Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Declines By 45.3%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 11,067 shares, a drop of 45.3% from the November 30th total of 20,224 shares. Based on an average daily trading volume, of 33,204 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s stock are short sold. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 33,204 shares, the short-interest ratio is presently 0.3 days.

Matinas Biopharma Stock Performance

Shares of NYSEAMERICAN:MTNB opened at $0.62 on Friday. The firm has a market capitalization of $3.97 million, a P/E ratio of -0.18 and a beta of 1.32. The stock has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.27. Matinas Biopharma has a 52-week low of $0.47 and a 52-week high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.